Teva Pharmaceuticals (NYSE:TEVA) and Alvotech (NASDAQ:ALVO) said on Monday that the U.S. FDA has approved Selarsdi injection, a biosimilar to Stelara, as an interchangeable treatment for inflammatory conditions.
Stelara is a registered under Johnson & Johnson (JNJ).
